Fig 1: Clusterin silencing and overexpression had no effect on apoptosis induced by MG132 in cardiomyocytes.a Representative control- and MG132-treated NCM (10 µmol/L, 18 h) observed by phase-contrast microscopy. b Representative western blots and quantification of Bcl2 and cleaved caspase-3 proteins levels in MG132-treated NCM (n = 5) compared to control cells (n = 6). c NCM were transfected with siRNA non-target (si-NT) or siRNA targeting clusterin (siClu-1 and siClu-2) for 48 h before MG132 treatment (10 µmol/L, 18 h). Representative western blots and quantification of Bcl2 and cleaved caspase-3 proteins levels in MG132-treated NCM after CLU silencing (n = 8 and 6 for siClu-1 and siClu-2, respectively) compared to siNT-transfected NCM (n = 8). Sarcomeric actin (S-actin) was used to normalize proteins levels and data are expressed as individual and mean fold change in proteins levels relative to siNT-transfected cells. d NCM were transfected by empty vector (pCMV6) or vector overexpressing the secreted isoform of clusterin (pCMV6 Clu) for 48 h before MG132 treatment. Representative western blots and quantification of Bcl2 and cleaved caspase-3 proteins levels in transfected cells in presence and absence of MG132 (n = 6/group). Sarcomeric actin (S-actin) was used to normalize proteins levels and data are expressed as individual and mean fold change in proteins levels relative to pCMV6-transfected cells. e TUNEL staining (scale bar: 100 µm) in pCMV6 and pCMV6 Clu- transfected cells in presence or absence of MG132 and quantification of the percentage of TUNEL-positive cells in these 4 conditions normalized by the data obtained in pCMV6 group. (n = 9/group). Statistical significance was determined by Wilcoxon–Mann Whitney test. *P < 0.05, **P < 0.01 vs. nonstimulated condition
Fig 2: Clusterin is degraded by proteasome and lysosome in cardiomyocytes.a Representative western blots and quantification of ubiquitinated proteins levels in NCM treated with cycloheximide (CHX, inhibitor of novo protein synthesis, 100 μg/mL) in presence or absence of MG132 (10 µmol/L) for 4 h compared to control cells (n = 6/group). b Representative western blots of LC3 and quantification of LC3II proteins levels in CHX-treated NCM in presence or absence of BAF (50 nmol/L) for 4 h compared to control cells (n = 6/group). c–e Representative western blots of intracellular CLU proteins levels and quantification of CLU mature form (m-CLU) levels in CHX-treated NCM in presence or absence of MG132 (c) or BAF (e) for 4 h compared to control cells (n = 6/group). For all intracellular proteins levels, sarcomeric actin (S-actin) was used to normalization. d–f Representative western blots and quantification of secreted CLU proteins levels (s-CLU) in CHX-treated NCM in presence or absence of MG132 (d) or BAF (e) for 4 h compared to control cells (n = 4/group). The culture medium is collected from the same cells after 24 h serum-deprivation corresponding to the beginning of treatment (T0h) and after 4 h of treatment (T4h). The levels of s-CLU quantified at T0h are used as normalizer. Graph show individual and mean fold change in proteins levels relative to control cells. Statistical significance was determined by Wilcoxon–Mann Whitney test. *P < 0.05, **P < 0.01 vs. control cells and #P < 0.05, ##P < 0.01 vs. CHX-treated cells
Fig 3: Inhibition of macroautophagy induction increased clusterin expression in MG132-treated cardiomyocytes.a, b Representative western blots and quantification of LC3 proteins levels, LC3II/LC3I ratio (a) and ubiquitinated proteins levels (b) in NCM treated with 3-methyladenine (3-MA, 10 mmol/L, 19 h) (n = 9) and/or MG132 (10 µmol/L, 18 h) (n = 9 and 13, respectively) compared to control cells (n = 13). c Analysis of clusterin (CLU) expression and secretion in NCM after the different treatments. Quantification by RT-qPCR, of CLU mRNA levels (upper panel) in the treated NCM (n = 8–9/group) compared to control cells (n = 8). Representative western blots and quantification of intracellular levels of precursor (p-CLU) and mature (m-CLU) forms of clusterin (n = 9 and 13/group, respectively) and its secreted form (s-CLU) (n = 8–9/group) in the treated NCM compared to control cells. For qPCR analysis, HPRT was used to normalize CLU expression and the data are expressed in arbitary units (A.U.). For western blot analysis, sarcomeric actin (S-actin) was used to normalize intracellular proteins levels and total mRNA levels were used to normalize secreted CLU levels. Data are expressed as individual and mean fold change in proteins levels relative to control cells. Statistical significance was determined by Wilcoxon–Mann Whitney test. *P < 0.05, ***P < 0.001 vs. control cells and #P < 0.05, ***P < 0.001 vs. MG132-treated cells
Fig 4: Increased clusterin expression in hypertrophied cardiomyocytes is associated with proteasome and macroautophagy inhibition.a Representative western blots and quantification of ubiquitinated proteins levels in NCM treated by isoproterenol (ISO, 10 µmol/L, 72 h) compared to control cells (n = 10/group). b Representative western blots of intracellular CLU proteins levels (precursor and mature forms) and its secreted form (top left panel) in NCM treated or not with ISO. Correlation of CLU precursor (top right panel), mature (bottom left panel) and secreted forms (bottom right panel) with ubiquitinated proteins levels in these cells. c Representative western blots and quantification of LC3 proteins levels and LC3II/LC3I ratio in ISO-treated NCM compared to control cells (n = 11/group). d Correlation of CLU precursor (left panel), mature (middle panel), and secreted form (right panel) with LC3II/LC3I ratio in NCM treated or not with ISO. For western blot analysis, sarcomeric actin (S-actin) was used to normalize proteins levels and data are expressed as individual and mean fold change in proteins levels relative to control cells. Statistical significance was determined by Wilcoxon–Mann Whitney or Spearman correlation test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. nonstimulated condition or indicated values
Fig 5: Increased Clusterin expression in human cardiac biopsies from control and heart failure patients is associated with proteasome and macroautophagy alteration.a Western Blot and quantification (left panels) of ubiquitinated proteins levels in LV biopsies obtained from human nonfailing controls (NF, n = 6) and heart failure patients (HF, n = 8). Correlation of CLU precursor and mature form with ubiquitinated proteins levels in these samples (right panels). b, c Analysis of macroautophagy in HF. Western Blot and quantification of LC3 proteins levels, LC3II/LC3I ratio (b), p62 and Beclin-1 proteins levels (c) in LV biopsies obtained from HF compared to NF patients. GAPDH was used to normalize all proteins levels and data are expressed as individual and mean fold change in proteins levels relative to NF patients. Statistical significance was determined by Wilcoxon–Mann Whitney or Spearman correlation test. *P < 0.05 vs. NF
Supplier Page from OriGene Technologies for Clu (NM_053021) Rat Untagged Clone